SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far

In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes.

[1]  Yi Fan,et al.  Bat Coronaviruses in China , 2019, Viruses.

[2]  W. Liang,et al.  Clinical characteristics of 2019 novel coronavirus infection in China , 2020, medRxiv.

[3]  J. Christie,et al.  Acute Respiratory Distress Syndrome Phenotypes , 2019, Seminars in Respiratory and Critical Care Medicine.

[4]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[5]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[6]  M. Lipsitch,et al.  Defining the Epidemiology of Covid-19 - Studies Needed. , 2020, The New England journal of medicine.

[7]  Christian Drosten,et al.  Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.

[8]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[9]  A. Aguilar-Shea,et al.  [COVID-19 and the hope for immunity]. , 2020, Atencion primaria.

[10]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[11]  M. Arbabi-Ghahroudi Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook , 2017, Front. Immunol..

[12]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[13]  Yichong Li,et al.  Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey , 2016, Journal of Epidemiology & Community Health.

[14]  Novel Coronavirus Pneumonia Emergency Response Epidemiol Team [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[15]  A. Dömling,et al.  Chemistry and Biology of SARS-CoV-2 , 2020, Chem.

[16]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[17]  R. Colwell,et al.  Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials , 2015, mBio.

[18]  Christian Drosten,et al.  The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells , 2020, bioRxiv.

[19]  Manar Mohammed El Tabaa,et al.  Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. , 2020 .

[20]  P. Hart,et al.  A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC) , 2019, Trials.

[21]  Elizabeth L. Beam,et al.  The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Wax,et al.  Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients , 2020, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[23]  I. Astuti,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[24]  Christian Drosten,et al.  Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response , 2011, Journal of Virology.

[25]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[26]  A. Maxmen More than 80 clinical trials launch to test coronavirus treatments , 2020, Nature.

[27]  D. Burton,et al.  Passive immunotherapy of viral infections: 'super-antibodies' enter the fray , 2018, Nature Reviews Immunology.

[28]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[29]  Giorgio Guzzetta,et al.  The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster , 2017, PloS one.

[30]  Jincun Zhao,et al.  A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry , 2010, Journal of Virology.

[31]  Hongzhou Lu,et al.  Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle , 2020, Journal of medical virology.

[32]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[33]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[34]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[35]  W. Zuo,et al.  Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov , 2020, bioRxiv.

[36]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[37]  Michael Proschan,et al.  A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.

[38]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[39]  P. Daszak,et al.  Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin , 2018, Nature.

[40]  K. Shadan,et al.  Available online: , 2012 .

[41]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[42]  S. Mulangu 843. The PALM Consortium: A Multicenter, Multioutbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics , 2019, Open Forum Infectious Diseases.

[43]  Natasha S Crowcroft,et al.  The basic reproduction number (R0) of measles: a systematic review. , 2017, The Lancet. Infectious diseases.

[44]  Jingping Yuan,et al.  Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. , 2020, JAMA.

[45]  David C. Yeo,et al.  Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays , 2020, Journal of Clinical Virology.

[46]  Akram Khan,et al.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome , 2017, Critical Care.

[47]  Don Klinkenberg,et al.  Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[48]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[49]  Timothy F. Leslie,et al.  Complexity of the Basic Reproduction Number (R0) , 2019, Emerging infectious diseases.

[50]  Fei Deng,et al.  Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.

[51]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[52]  D. Atanackovic,et al.  A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer , 2019, Cancer Immunology, Immunotherapy.

[53]  O. Jahn,et al.  TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2013, Journal of Virology.

[54]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[55]  A. Al-Tammemi,et al.  The Battle Against COVID-19 in Jordan: An Early Overview of the Jordanian Experience , 2020, Frontiers in Public Health.

[56]  B. Prabhakar,et al.  Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing , 2012, PloS one.

[57]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[58]  L. Yang,et al.  Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak , 2020, International Journal of Infectious Diseases.

[59]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[60]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[61]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[62]  A. Gurung,et al.  Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach , 2020, Life Sciences.

[63]  U. Şahin,et al.  mRNA: A Versatile Molecule for Cancer Vaccines. , 2017, Current issues in molecular biology.

[64]  William B. Karesh,et al.  Stability of Middle East Respiratory Syndrome Coronavirus in Milk , 2014, Emerging infectious diseases.

[65]  D. Cyranoski Did pangolins spread the China coronavirus to people? , 2020 .

[66]  Yanchen Zhou,et al.  Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.

[67]  Jens H. Kuhn,et al.  Retroviruses Pseudotyped with the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Efficiently Infect Cells Expressing Angiotensin-Converting Enzyme 2 , 2004, Journal of Virology.

[68]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[69]  China Cdc Weekly The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 , 2020, China CDC weekly.

[70]  G. Gao,et al.  A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020 , 2020, China CDC weekly.

[71]  K. Iwakiri,et al.  Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities , 2018, Digestion.

[72]  G. Kampf,et al.  Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents , 2020, Journal of Hospital Infection.

[73]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[74]  G. Cai Tobacco-Use Disparity in Gene Expression of ACE2, the Receptor of 2019-nCov , 2020 .

[75]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.